US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
PT909323E
(pt)
|
1996-01-04 |
2007-06-04 |
Novartis Vaccines & Diagnostic |
''bacterioferritina de helicobacter pilori''
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
WO1999061056A2
(en)
|
1998-05-22 |
1999-12-02 |
Loeb Health Research Institute At The Ottawa Hospital |
Methods and products for inducing mucosal immunity
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
ATE376825T1
(de)
*
|
1999-09-24 |
2007-11-15 |
Glaxosmithkline Biolog Sa |
Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
|
BR0014285A
(pt)
*
|
1999-09-24 |
2002-05-21 |
Smithkline Beecham Biolog |
Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
|
AU3108001A
(en)
*
|
2000-01-20 |
2001-12-24 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
CZ303468B6
(cs)
|
2000-02-23 |
2012-10-03 |
Smithkline Beecham Biologicals S. A. |
Imunogenní smes a farmaceutická smes
|
MXPA02011486A
(es)
|
2000-05-19 |
2004-01-26 |
Corixa Corp |
Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido.
|
ATE442866T1
(de)
|
2000-06-20 |
2009-10-15 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
AU1591402A
(en)
*
|
2000-10-02 |
2002-04-15 |
Smithkline Beecham Biolog |
Vaccine
|
DE60139563D1
(de)
|
2000-10-27 |
2009-09-24 |
Craig J Venter Inst Inc |
Nukleinsäuren und proteine von gruppen a und b-streptokokken
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
CA2439111A1
(en)
*
|
2001-04-05 |
2002-10-17 |
Chiron Corporation |
Mucosal boosting following parenteral priming
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
CN1636015A
(zh)
|
2001-06-29 |
2005-07-06 |
希龙公司 |
Hcv e1e2疫苗组合物
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
DK2224012T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
US8088388B2
(en)
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
EP1387167B1
(en)
*
|
2002-07-24 |
2008-05-07 |
Centre National De La Recherche Scientifique (Cnrs) |
Method for identifying biologically active compounds with anti-asthmatic and/or anti-allergic properties
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US20040132652A1
(en)
*
|
2002-08-30 |
2004-07-08 |
Shire Biochem Inc. |
Pharmaceutical compositions
|
DE60335477D1
(de)
|
2002-10-11 |
2011-02-03 |
Novartis Vaccines & Diagnostic |
Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
|
EP2241325B1
(en)
|
2002-10-29 |
2012-02-08 |
Coley Pharmaceutical Group, Inc. |
Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
|
CA2506318C
(en)
|
2002-11-15 |
2011-07-12 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US8034378B2
(en)
|
2002-12-27 |
2011-10-11 |
Novartis Vaccines And Diagnostics, Inc |
Immunogenic compositions containing phospholipid
|
EP2940028B8
(en)
|
2003-01-06 |
2017-09-27 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2004092360A2
(en)
|
2003-04-10 |
2004-10-28 |
Chiron Corporation |
The severe acute respiratory syndrome coronavirus
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
DE602004032481D1
(de)
|
2003-10-02 |
2011-06-09 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen Meningitis
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
US7399467B2
(en)
|
2003-12-23 |
2008-07-15 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of HPV and methods of their use
|
JP5600375B2
(ja)
|
2004-03-09 |
2014-10-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
インフルエンザウイルスワクチン
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
JP5718545B2
(ja)
|
2004-04-30 |
2015-05-13 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
髄膜炎菌結合体ワクチン接種
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP1855715B1
(en)
|
2005-01-27 |
2013-03-13 |
Children's Hospital & Research Center at Oakland |
Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
EP2351772B1
(en)
|
2005-02-18 |
2016-07-13 |
GlaxoSmithKline Biologicals SA |
Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
CN103372206A
(zh)
|
2005-03-31 |
2013-10-30 |
葛兰素史密丝克莱恩生物有限公司 |
针对衣原体感染的疫苗
|
ZA200800146B
(en)
*
|
2005-08-03 |
2009-10-28 |
Immunogen Inc |
Immunoconjugate formulations
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
EP1776963A1
(en)
*
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
US10842867B2
(en)
|
2005-11-04 |
2020-11-24 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
NZ570106A
(en)
|
2006-01-27 |
2012-04-27 |
Novartis Vaccines & Diagnostic |
Influenza vaccines containing hemagglutinin and matrix proteins
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
EP1897557A1
(en)
*
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
EP2497495B3
(en)
|
2006-09-11 |
2021-02-17 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
PL2121011T3
(pl)
|
2006-12-06 |
2014-10-31 |
Novartis Ag |
Szczepionki zawierające antygeny czterech szczepów wirusa grypy
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2136836T3
(en)
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
ES2393162T3
(es)
|
2007-06-27 |
2012-12-19 |
Novartis Ag |
Vacunas antigripales con un contenido reducido de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
CN101795709B
(zh)
|
2007-08-02 |
2013-07-17 |
彼昂德瓦克斯医药有限公司 |
多亚基多表位流感疫苗
|
US20100260791A1
(en)
|
2007-08-03 |
2010-10-14 |
President And Fellows Of Harvard |
Chlamydia antigens
|
EP2197485B1
(en)
|
2007-09-12 |
2015-11-11 |
GlaxoSmithKline Biologicals SA |
Gas57 mutant antigens and gas57 antibodies
|
EP2224954B1
(en)
|
2007-11-07 |
2014-01-08 |
Celldex Therapeutics, Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8637053B2
(en)
|
2007-12-03 |
2014-01-28 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
EP2244695A1
(en)
|
2007-12-07 |
2010-11-03 |
Novartis AG |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
PL2235046T3
(pl)
|
2007-12-21 |
2012-12-31 |
Novartis Ag |
Zmutowane formy streptolizyny O
|
EP2245048B1
(en)
|
2008-02-21 |
2014-12-31 |
Novartis AG |
Meningococcal fhbp polypeptides
|
EP2265640B1
(en)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
EP2356225A1
(en)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
MX2011006077A
(es)
|
2008-12-09 |
2011-09-01 |
Pfizer Vaccines Llc |
Vacuna de peptido ch3 de ige.
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
AU2010220103A1
(en)
|
2009-03-06 |
2011-09-22 |
Novartis Ag |
Chlamydia antigens
|
MX363222B
(es)
|
2009-04-14 |
2019-03-15 |
Novartis Ag |
Composiciones para inmunizacion contra staphylococcus aureus.
|
US20120052088A1
(en)
|
2009-04-30 |
2012-03-01 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
SG176532A1
(en)
|
2009-06-15 |
2012-01-30 |
Univ Singapore |
Influenza vaccine, composition, and methods of use
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
CN102770443A
(zh)
|
2009-07-16 |
2012-11-07 |
诺华有限公司 |
脱毒大肠杆菌免疫原
|
NZ598356A
(en)
|
2009-07-30 |
2014-06-27 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
CN102596240B
(zh)
|
2009-08-27 |
2015-02-04 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
TR201808222T4
(tr)
|
2009-09-03 |
2018-07-23 |
Pfizer Vaccines Llc |
PCSK9 aşısı.
|
MX338753B
(es)
|
2009-09-30 |
2016-04-29 |
Novartis Ag |
Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
AU2010310985B2
(en)
|
2009-10-27 |
2014-11-06 |
Glaxosmithkline Biologicals S.A. |
Modified meningococcal fHBP polypeptides
|
WO2011056899A2
(en)
|
2009-11-03 |
2011-05-12 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
EP3257525A3
(en)
|
2009-12-22 |
2018-02-28 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
CN114634557A
(zh)
|
2010-03-30 |
2022-06-17 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白(fhbp)及其使用方法
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9744228B2
(en)
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
LT3023106T
(lt)
*
|
2010-12-14 |
2019-10-25 |
Glaxosmithkline Biologicals Sa |
Mikobakterinė antigeninė kompozicija
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
DK2667892T3
(da)
|
2011-01-26 |
2019-05-13 |
Glaxosmithkline Biologicals Sa |
RSV-vaccineringsprogram
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
SG194755A1
(en)
|
2011-05-13 |
2013-12-30 |
Novartis Ag |
Pre-fusion rsv f antigens
|
EP2723365A1
(en)
|
2011-06-21 |
2014-04-30 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
CN103930436A
(zh)
|
2011-09-14 |
2014-07-16 |
诺华股份有限公司 |
大肠杆菌疫苗组合
|
CA2858519A1
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
JP2015509713A
(ja)
|
2012-02-24 |
2015-04-02 |
ノバルティス アーゲー |
線毛タンパク質および組成物
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
KR102139959B1
(ko)
|
2012-04-26 |
2020-08-04 |
노파르티스 아게 |
항원 및 항원 조합물
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
KR20200075023A
(ko)
|
2012-05-04 |
2020-06-25 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
SG10201608675YA
(en)
|
2012-05-22 |
2016-12-29 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
MX2015001557A
(es)
|
2012-08-03 |
2015-10-08 |
Infectious Disease Res Inst |
Composiciones y metodos para tratar una infeccion activa por mycobacterium tuberculosis.
|
SG11201502197XA
(en)
|
2012-10-02 |
2015-04-29 |
Glaxosmithkline Biolog Sa |
Nonlinear saccharide conjugates
|
CN104582718B
(zh)
|
2012-10-03 |
2017-10-24 |
诺华股份有限公司 |
免疫原性组合物
|
SG10201706671WA
(en)
|
2012-11-30 |
2017-09-28 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
JP2016520077A
(ja)
|
2013-05-15 |
2016-07-11 |
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ |
E1e2hcvワクチン及び使用方法
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
PE20212335A1
(es)
|
2014-01-21 |
2021-12-16 |
Pfizer |
Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
JP6796057B2
(ja)
|
2014-07-23 |
2020-12-02 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
H因子結合タンパク質変異体及びその使用方法
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
PL3233912T3
(pl)
|
2014-12-19 |
2021-12-27 |
Regenesance B.V. |
Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
|
IL252915B2
(en)
|
2015-01-15 |
2024-04-01 |
Pfizer |
Immunogenic preparations for use in pneumococcal vaccines
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
MX2017015004A
(es)
|
2015-05-26 |
2018-07-06 |
Ohio State Innovation Foundation |
Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
|
EP3302536A1
(en)
|
2015-06-03 |
2018-04-11 |
Affiris AG |
Il-23-p19 vaccines
|
JP2018522885A
(ja)
|
2015-07-07 |
2018-08-16 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IgE介在性疾患の処置および予防のためのワクチン
|
RU2721128C2
(ru)
|
2015-07-21 |
2020-05-18 |
Пфайзер Инк. |
Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
KR102158923B1
(ko)
|
2016-01-19 |
2020-09-23 |
화이자 인코포레이티드 |
암 백신
|
CA3021328A1
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
CN109310748A
(zh)
|
2016-05-21 |
2019-02-05 |
传染病研究所 |
用于治疗继发性结核和非结核分枝杆菌感染的组合物和方法
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
KR102459629B1
(ko)
|
2017-01-20 |
2022-10-28 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
JP2021502350A
(ja)
|
2017-11-03 |
2021-01-28 |
タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. |
ジカワクチン及び免疫原性組成物、ならびにその使用方法
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
CA3097369A1
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
US20220016168A1
(en)
|
2018-12-11 |
2022-01-20 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
US20230000966A1
(en)
|
2019-11-01 |
2023-01-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
NL2027383B1
(en)
|
2020-01-24 |
2022-04-06 |
Aim Immunotech Inc |
Methods, compositions, and vaccines for treating a virus infection
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2023514825A
(ja)
|
2020-02-26 |
2023-04-11 |
ヴェルシテック リミテッド |
コロナウイルス感染症に対するpd-1ベースのワクチン
|
CN116724118A
(zh)
*
|
2020-07-24 |
2023-09-08 |
利兰斯坦福初级大学董事会 |
Covid-19的三组分疫苗
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
KR20230147075A
(ko)
|
2021-02-19 |
2023-10-20 |
사노피 파스퇴르 인크 |
수막구균 b 재조합 백신
|
EP4320159A1
(en)
|
2021-04-09 |
2024-02-14 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
US20240226280A1
(en)
|
2021-05-04 |
2024-07-11 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
PE20240090A1
(es)
|
2021-05-28 |
2024-01-16 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
IL312890A
(en)
|
2021-11-18 |
2024-07-01 |
Matrivax Inc |
Immunogenic fusion protein preparations and methods of using them
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102420201B1
(ko)
*
|
2022-01-17 |
2022-07-13 |
주식회사 유이케미칼 |
인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024130009A1
(en)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions and methods of use thereof for the treatment of virally driven cancers
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|